Jazz Pharmaceuticals plc
NASDAQ:JAZZBiotechnology
+$0.05 today
- Market cap
- $15.90B
- Beta
- 0.33
- P/E (TTM)
- 476.3
- EPS (TTM)
- $0.48
Volume 0.72M
Average 0.92M
JAZZ Net Income
Bottom-line profit after all expenses, interest, and taxes.
Jazz Pharmaceuticals plcNASDAQ: JAZZ
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income turns negative
Q3 FY2026 net income was -$483.4M, compared with $251.41M a year earlier. Trailing-twelve-month net income was $205.95M.
Context
- Net income amounted to 8.3% of revenue in FY2025, down 5.4 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 16 analysts of $1.03B (+390.2%) for the fiscal year ending Dec 2026, a step up from the -163.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$483.4M-350.7% QoQ
- Last fiscal yearDec 2025
- -$356.15M-163.6% YoY
- LTMSep 2026
- $205.95M+155.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -292.3% | +121.8% | +414.1 pp |
| 1 year | -163.6% | +390.2% | +553.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (356.15M) USD
- Year-over-year change
- -163.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (356.15M) | -163.6% |
| FY2024 | 2024-12-31 | 560.12M | +35.0% |
| FY2023 | 2023-12-31 | 414.83M | +285.1% |
| FY2022 | 2022-12-31 | (224.06M) | +31.9% |
| FY2021 | 2021-12-31 | (328.95M) | — |
Net Income vs competitors
How JAZZ compares with its peers on the latest reported figures
- JAZZ's LTM Sep 2026 net income of $205.95M is the 4th highest of the 9 companies compared; the peer median is $189.25M.
- Its year-over-year change of +155.9% is the 2nd highest of 8, against a peer median of +64.1%.
- Net income amounts to 4.4% of revenue for JAZZ, versus a peer median of 19.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.61B | +85.1% | +55.7% | 27.7% | |
| LTM Jun 2026 | $788.1M | — | -43.9% | 19.1% | |
| LTM Sep 2026 | $702.5M | +64.1% | +45.8% | 19.0% | |
| LTM Sep 2026 | $205.95M | +155.9% | — | 4.4% | |
| LTM Jun 2026 | $197.22M | +360.0% | — | 67.9% | |
| LTM Jun 2026 | $181.27M | +0.2% | -4.4% | 18.9% | |
| LTM Sep 2026 | $106.06M | -76.3% | — | 11.8% | |
| LTM Sep 2026 | -$215K | +99.9% | — | 0.0% | |
| LTM Mar 2026 | -$70.36M | -26.1% | — | 44.8% | |
| Peer median (excluding JAZZ) | $189.25M | +64.1% | +20.7% | 19.0% | |
Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.09B | 3.66B | 3.83B | 4.07B | 4.27B |
| Cost of Revenue | 440.76M | 540.52M | 435.58M | 445.71M | 503.3M |
| Gross Profit | 2.65B | 3.12B | 3.4B | 3.62B | 3.76B |
| Gross Margin | 85.8% | 85.2% | 88.6% | 89.0% | 88.2% |
| Research & Development | 505.75M | 590.45M | 849.66M | 884M | 782.74M |
| Selling, General & Admin | 1.45B | 1.42B | 1.34B | 1.39B | 1.81B |
| Operating Expenses | 2.48B | 3.18B | 2.82B | 2.91B | 3.54B |
| Depreciation & Amortization | 552.48M | 629.47M | 638.7M | 660.07M | 696.3M |
| EBITDA | 1.03B | 1.47B | 1.45B | 1.52B | 262.76M |
| EBITDA Margin | 33.2% | 40.1% | 37.8% | 37.4% | 6.2% |
| Operating Income | 170.28M | (65.53M) | 578.58M | 716.63M | 224.42M |
| Operating Margin | 5.5% | -1.8% | 15.1% | 17.6% | 5.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 278.77M | 288.24M | 289.44M | 238.1M | 195.05M |
| Other Income / Expenses | (283.83M) | (317.18M) | (283.66M) | (247.94M) | (853.01M) |
| Income Before Tax | (113.55M) | (382.71M) | 294.92M | 468.69M | (628.59M) |
| Pre-Tax Margin | -3.7% | -10.5% | 7.7% | 11.5% | -14.7% |
| Income Tax Expense | 216.12M | (158.65M) | (119.91M) | (91.43M) | (272.44M) |
| Net Income | (328.95M) | (224.06M) | 414.83M | 560.12M | (356.15M) |
| Net Margin | -10.6% | -6.1% | 10.8% | 13.8% | -8.3% |
| EPS (Basic) | (5.51) | (3.58) | 6.55 | 9.06 | (5.84) |
| EPS (Diluted) | (5.51) | (3.58) | 6.10 | 8.65 | (5.84) |
| Weighted Avg Shares | 59.69M | 62.54M | 63.29M | 61.84M | 60.98M |
| Weighted Avg Shares (Diluted) | 59.69M | 62.54M | 72.07M | 66.01M | 60.98M |
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
Intrinsic Alpha fair value
Locked
Current Price
$247.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.